NCT07184645View on ClinicalTrials.gov

A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

OPA-15406

0.3% foam or 1% foam, topical, twice daily, for 8 weeks

DRUG

Vehicle

vehicle, topical, twice daily, for 8 weeks

Trial Locations (1)

Unknown

Sumire Dermatology Clinic, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY